Replies to post #193069 on Biotech Values

[masterlongevity]

BIIB gets 30%

[linhdtu]

Rarely would these comparative trials use the more effective and/or newer drugs. Always either placebo or something outdated.
Kinda setting oneself up for a fight NOT with someone my own size but a teen or most likely a wheezing geezer.

But then I understand the game by now.lol.

[DewDiligence]

Roche’s Ocrelizumab succeeds in PPMS—the first drug to do so in a phase-3 trial:

http://www.reuters.com/article/2015/09/28/us-roche-multiple-sclerosis-idUSKCN0RS0KL20150928

Results from a pivotal Phase III study of the drug in PPMS showed that treatment with ocrelizumab significantly reduced the progression of clinical disability and the effect was sustained for at least 12 weeks. The incidence of serious adverse events associated with ocrelizumab, including serious infections, was also similar to placebo.

…Ocrelizumab is delivered twice-yearly via an intravenous drip. As an antibody-based medicine it is likely to be expensive but Roche, the world's biggest cancer drugs company, has not yet given any indications on price.

As a consequence of the longrunning CD20 (Rituxan) collaboration between Genenetch and Idec Pharmaceuticals, BIIB gets an approximate 30% share of US net profits on Ocrelizumab (not to be confused with a 30% royalty on sales).